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Introduction
Thrombosis in pediatric patients has an increasing rate of incidence, especially in
hospitalized patients. On the one hand, this is due to increasing complications of
care of critically ill children and neonates, and, on the other hand, due to more
awareness and sensitive diagnostic tools which identify thrombosis.1
The most substantial risk factor for venous thromboembolism (VTE) in children
has been described as central venous access devices (CVAD). However, pediatric VTE
not only occurs with congenital heart disease, trauma and surgery, infection (local or
systemic), malignancy, prematurity, oral contraceptives, immobilization, in the pre-
sence of antiphospholipid antibodies, but also with inherited thrombophilia.2–5
Treatment of VTE in the pediatric setting is in most cases not evidence based, as
well-designed clinical trials in pediatric populations and studies on anticoagulants
have not been performed extensively. For this reason, treatment guidelines are
mainly extrapolated from adult studies. However, the pathophysiology of VTE,
the hemostatic system, and the underlying medical conditions of children are
substantially different from those of adults.6 This means also that complications
from anticoagulation treatments such as bleeding risks may differ from adult
patients.
The current standard of care for the treatment of VTE in children includes low
molecular weight heparin (LMWH), unfractionated heparin (UFH), and vitamin
K antagonists (VKA). Depending on the center of care and the available expertise
and experience, local, systemic thrombolysis and/or physical thrombectomy may be
available and performed.7–9
In this review, we summarize and compare recommendations for the treatment
of several VTE manifestations in children from the CHEST, ASH, and UK
Correspondence: Manuela Albisetti
Division of Hematology, University
Children’s Hospital, Steinwiesstrasse 75,
Zurich CH-8032, Switzerland
Tel +41 44 266 7138
Fax +41 44 266 7171
Email Manuela.albisetti@kispi.uzh.ch
Therapeutics and Clinical Risk Management Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Therapeutics and Clinical Risk Management 2020:16 673–679 673
http://doi.org/10.2147/TCRM.S218622
DovePress © 2020 Bosch and Albisetti. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/
terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing
the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
guidelines.7–9 The new direct oral anticoagulants
(DOACs) are not considered in this review, as these are




The CHEST, ASH, and UK guidelines base their recom-
mendations on the GRADE system. UK and CHEST clas-
sify their strong recommendations as “1” and their
conditional recommendations or suggestions as “2,” while
ASH classifies these as “strong recommendation” and as
“conditional recommendation,” respectively. Strong recom-
mendations are based on desirable effects of a treatment that
outweigh the harms and costs, whereas conditional recom-
mendations are made, if only low-quality evidence is avail-
able, and the benefits are uncertain, or the harm of treatment
outweighs the desirable effects.6–8,10
CHEST and UK guidelines further grade the quality of
evidence as A (high quality: based on randomized clinical
trials; further research results will be unlikely to change the
actual standard), moderate B (further research outputs may
change the current standards), and low C (further research
outputs will very likely change the current standards). ASH
grades the quality of evidence from low to high. To main-
tain manageable reading, we will refer to ASH’s strong as
“1” and conditional recommendation as “2,” and the quality
of evidence from high to low as “A to C,” respectively.6–8,10
An overview of the recommendations on the manage-
ment of venous thromboembolism in children is given in
Table 1, whereas the therapeutic options are summarized
in Table 2.
CVAD-Associated Thrombosis
Due to limited venous access conditions, pediatric patients
often rely on CVAD. If a symptomatic thrombosis occurs,
the patient requires CVAD and the device is functional, ASH
suggests leaving the CVAD in situ (2C), in line with CHEST
which suggests either initial anticoagulation therapy or radi-
ologic monitoring after diagnosis of a CVAD-thrombosis
(2C), and if the thrombus progresses, anticoagulation is sug-
gested (2C). In the case of anticoagulation, the CHEST guide-
line suggests the administration of LMWH or UFH for a total
duration of 6 weeks to 3 months (2C). CVAD-related super-
ficial vein thrombosis should be treated if the CVAD is func-
tioning and further required, and/or in patients with worsening
symptoms (ASH 2C).
If the symptoms progress under anticoagulation ther-
apy, the CVAD is further required by the patient and is still
functioning, ASH suggests either removal or no removal
(2C). If alternative venous access is available, the CVAD
should be removed. If no alternative is accessible, the
CVAD should stay in situ with the risk of infection and
thrombus progression.
Should a CVAD remain in situ after therapy comple-
tion, prophylactic anticoagulation with VKA or LMWH is
suggested by CHEST until CVAD removal (2C). Should
the thrombosis recur during prophylactic therapy, CHEST
suggests further therapeutic anticoagulation until the
CVAD is removed or for a minimum of 3 months (2C).
CHEST suggests against thrombolytic therapies, unless
a limb, organ, or life is threatened by the thrombus (2C).
If the CVAD does not function, or is no longer needed
by the patient, ASH and CHEST recommend removing the
CVAD (ASH 1C, CHEST 1B). However, the removal
should be delayed if the dysfunction is related to
a thrombus, due to the risk of thrombus embolization.
After several days of initiation of an anticoagulation ther-
apy the device should be removed (ASH 2C). The UK
guideline suggests the removal after 2–4 days (2C), while
CHEST suggests the removal 3–5 days after the start with
therapeutic anticoagulation (2C).
For a right-atrial CVAD-related thrombus, CHEST sug-
gests the removal of the CVAD with or without previous
anticoagulation (2C), and depending on the size and the
patient risks a surgical intervention (2C).
Primary prevention of CVAD-related thrombosis is not
suggested by the UK guideline (2B), whereas it suggests
the consideration of the use of heparin-bonded CVADs for
short-term use (2C). CHEST also recommends against
thrombo-prophylaxis for children with short-term CVADs
(1B). CHEST suggests regular CVAD-flushing with saline
or heparin or intermittent recombinant urokinase (2C). For
blocked CVADs, CHEST recommends one or two recom-
binant urokinase or tissue plasminogen activator trials to
restore the patency (2C). If CVAD is further dysfunctional,
radiologic imaging is advised to rule out CVAD-related
thrombosis (2C).
In neonates, CHEST recommends an UFH-continuous
infusion to maintain CVAD function (1A), and for CVAD-
dysfunction in neonates, local thrombolysis with tissue
plasminogen activator is suggested (2C).
CHEST further suggests VKA thromboprophylaxis in
children over 1 year of age receiving parenteral nutrition
via a CVAD (2C).
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Table 1 Comparison of Guideline Recommendations on the Management of Venous Thromboembolism in Children











● Remove CVAD if alternate
venous access is available
● Remove several days after
start of anticoagulation
● Anticoagulation or radiologic monitoring
● Anticoagulation if thrombus progresses
● Remove 3–5 days after start of
anticoagulation
● Therapy duration 6 weeks–3 months
● Prophylaxis after therapy is completed,
until CVAD is removed
● Right atrial CVAD thrombus: remove
CVAD, with or without prior anticoa-
gulation; ± surgical intervention
● Remove 2–4 days after start of
anticoagulation





● Asymptomatic: no therapy or
therapeutic anticoagulation
● Therapy duration 3 months
or less
● 6–12 months for unprovoked
DVT/PE
● No thrombolysis, thrombect-
omy or inferior vena cava
filters
● In massive PE: thrombolysis
and subsequent anticoagula-
tion, no thrombectomy
● Therapy duration 3 months for pro-
voked VTE
● 6–12 months for unprovoked DVT/PE
● Therapeutic or prophylactic anticoagu-
lation beyond the 3-month baseline
therapy for provoked DVT/PE, until the
risk factors have resolved
● VKA life-long for idiopathic VTE and
antiphospholipid syndrome
● IVC-filter only in children >10 kg and
with contraindication to anticoagula-
tion-therapy
● Therapy duration 3 months
● 6 months for unprovoked DVT/
PE
● Indefinite anticoagulation in
idiopathic VTE and antipho-
spholipid syndrome
● Consideration of thrombolytic
therapy in extensive thrombosis





● Anticoagulation in CSVT with
hemorrhage
● No thrombolysis
● Anticoagulation in CSVTwith significant
hemorrhage, or radiologic monitoring
to detect thrombus progression after
5–7 days, then anticoagulation
● Thrombolysis, thrombectomy or surgi-
cal decompression only if UFH-therapy
fails
● Anticoagulation in CSVT with
hemorrhage, no anticoagulation
in hemorrhage with mass effect
or intraventricular hemorrhage.
● Radiologic monitoring in CSVT
with significant hemorrhage to
detect thrombus progression
after 5–7 days, then anticoagu-


















● Anticoagulation rather than
no therapy and rather than
thrombolysis
● In life threatening RVT:
Thrombolysis +
anticoagulation
● Radiologic monitoring or anticoagulation
● Anticoagulation upon thrombus
progression








● Protein C replacement ther-
apy with or without
anticoagulation
● FFP or protein C concentrate until
lesions clear
● Lifelong anticoagulation with VKA or
LMWH, protein C replacement or
liver transplant.
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Table 2 Therapeutic Options on Specific Pediatric Venous Thromboembolic Events





















● VKA prophylaxis in










● UFH if rapid reversal
is necessary (UK)
● UFH/LMWH as ther-
apy (CHEST)
● LMWH for infants
<1 year (UK)

























● IVC filter in chil-



























with VTE risk fac-
tors (UK)














● in CSVTwithout rele-
vant hemorrhage
(ASH, CHEST, UK)
for at least 3 months
(CHEST, UK)
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Major Deep Vein Thrombosis (DVT) and
Pulmonary Embolism (PE)
In asymptomatic DVT and PE, ASH suggests either ther-
apeutic anticoagulation or no therapy (2C).
ASH and CHEST recommend therapeutic anticoagula-
tion in patients with symptomatic DVT or PE (ASH 1C;
CHEST 1B). The therapy for symptomatic DVT and PE
should consist of UFH or LMWH for at least 5 days
according to the CHEST recommendations (1B). UFH
can be administered initially if a rapid reversal of antic-
oagulation is necessary (UK 2C). Afterward, LMWH or
UFH are recommended by CHEST, whereas ASH suggests
LMWH or oral VKAs (2C). UK suggests LMWH as the
therapy of choice in infants under the age of 1 year (2C).
ASH advises against antithrombin (AT) replacement in
addition to standard anticoagulation. Anticoagulation
alone should be used in patients with DVT, PE (2C).
However, if therapy failure occurs clinically during stan-
dard anticoagulation alone and AT levels are low, AT
replacement is suggested (2C).
For UFH a therapeutic range is defined as an anti-Xa
activity of 0.35–0.7 U/mL (CHEST 2C), and CHEST
suggests avoiding long-term use of UFH in children
(2C). For LMWH the therapeutic range is defined as an
anti-Xa activity of 0.5–1.0 U/mL 4–6 hours after s.c.
injection (CHEST 2C). For oral VKA-therapy, a start as
early as day 1 is recommended, with the continuation of
LMWH/UFH until at least day 6, or later if the INR does
not exceed 2.0 on day 6 (1B CHEST). ASH suggests either
LMWH or VKA as the standard DVT/PE anticoagulation
therapy aiming at a goal-INR of 2.5 (ASH 2, UK 1B).
According to CHEST, the therapeutic range for VKA is
best monitored via the INR in a range of 2.0–3.0 (2C).
A therapy duration of 3 months or less (ASH 2C) or
3 months according to CHEST for provoked DVT seems
sufficient (2C), while unprovoked DVT or PE should be
treated for 6–12 months (ASH 2C and CHEST 2C),
whereas the UK recommends 3 months and 6 months,
respectively (1C). For VTE occurring in the presence of
thrombophilic risk factors (e.g. nephrotic syndrome/aspar-
aginase therapy), the intensity and duration of therapy
should be the same as in the absence of these. According
to the CHEST suggestion, in children with VTE or recur-
rent VTE and ongoing risk factors for thrombotic events,
either therapeutic or prophylactic anticoagulation is sug-
gested beyond the 3-month baseline therapy, until the risk
factors have resolved (2C). In recurrent unprovoked VTE
and pediatric patients with antiphospholipid syndrome,
indefinite anticoagulation is recommended (UK 1C).
CHEST recommends a life-long VKA treatment (1A).
ASH discourages the use of thrombolysis, thrombectomy,
or inferior vena cava filters in children with DVT and/or PE,
and rather recommends anticoagulation alone (2C). On the
other hand, in massive PE, i.e., patients with hemodynamic
compromise, thrombolysis and subsequent anticoagulation
are suggested, while thrombectomy is discouraged in the
ASH guidelines (2C). The UK guidelines recommend con-
sideration of thrombolytic therapy in extensive thrombosis in
pelvic veins, superior and inferior vena cava (SVC and IVC)
and in intracardiac sites, as well as in massive PE (1C). In
older children with contraindications for systemic anticoagu-
lation and DVT in lower limbs, removable IVC filters should
Table 2 (Continued).




































● or liver transplant
(ASH, CHEST)
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be considered (1C). This is in line with CHEST, which
suggests an IVC-filter only in children >10 kg and with
contraindication to anticoagulation therapy (2C). ASH sug-
gests against IVC-filters, and rather anticoagulation alone
should be considered as a treatment for symptomatic DVT
(2C). CHEST and ASH agree that thrombolysis should only
be performed if the life, organ, or limb of a patient is threa-
tened (CHEST 2C, ASH 2). UK suggests thrombolytic ther-
apy to be considered if extensive thrombosis occurs in the
IVC, SVC, pelvic veins, intracardial, or with massive PE
(1C). Further, CHEST suggests that thrombectomy be only
performed in life-threatening thrombosis, followed by stan-
dard anticoagulation therapy (2C).
Children and adolescents with numerous VTE risk fac-
tors should be considered for LMWH-prophylaxis (UK 2C).
The UK advises against aspirin in VTE-prophylaxis (2C).
The UK guidelines also recommend physical methods to
reduce VTE risk in older children and adolescents who are
at risk (1C). Especially in children with a high risk and under
anticoagulation-prophylaxis, physical methods can comple-
ment the prevention (2C).
Central Sino Venous Thrombosis (CSVT)
ASH recommends anticoagulation therapy in CSVT with-
out hemorrhage (1C), in line with the CHEST and UK
guidelines, which specify the therapeutic approach with
LMWH or UFH (1B). UK recommends VKA therapy with
INR goal 2.5 in children >1 year old (1C) and suggests
LMWH therapy in children <1 year (2C). This is in line
with the CHEST neonatal recommendation.
Further, ASH suggests anticoagulation therapy in
CSVT with hemorrhage (2C), while the UK guidelines
distinguish CSVT hemorrhage with and without mass
effect or intraventricular hemorrhage. UK discourages
anticoagulation in CSVT with relevant hemorrhage and
rather suggests radiologic monitoring. Further, UK sug-
gests treatment in less significant hemorrhage and infarc-
tion (2C). CHEST suggests anticoagulation in CSVT with
significant hemorrhage, or radiologic monitoring to detect
thrombus progression after 5–7 days. If thrombus progres-
sion occurs, anticoagulation is suggested (2C). ASH and
UK advise against thrombolysis (ASH 2C; UK 1C).
CHEST suggests thrombolysis, thrombectomy, or surgical
decompression only if UFH-therapy fails to improve the
clinical presentation or in severe CSVT (2C).
CHEST suggests a treatment duration of at least
3 months. The UK guidelines further suggest a therapy
duration of 3 months in CSVT with an identifiable risk
factor (e.g. infection) (1C); 6 months without risk factor
(1C) or longer if the risk factor is ongoing (e.g. asparagi-
nase therapy), recurrent idiopathic CSVTs occur, or the
patient remains symptomatic with venous hypertension
(UK 2C). This is in line with CHEST’s recommendation
(2C). CHEST also suggests prophylactic anticoagulation in
patients with recurring risk factors (asparaginase/nephrotic
syndrome) at times of exposure (2C).
In patients with persistent venous-hypertension symp-
toms, reimaging should be performed before anticoagula-
tion is terminated. Also, reimaging should be considered if
neurologic symptoms progress (UK 2C).
Other Thrombotic Events
Right Atrial Thrombosis (Non-CVAD Related)
ASH suggests anticoagulation therapy and advises against
thrombolysis or surgical thrombectomy (2C).
Portal Vein Thrombosis (PVT)
ASH recommends anticoagulation with occlusive throm-
bosis, post liver transplant, or spontaneous PVT, whereas
no therapy is suggested in non-occlusive PVT or portal
hypertension (2C).
Neonatal Renal Vein Thrombosis (RVT)
For unilateral RVT without organ impairment, the CHEST
guideline proposes radiologic monitoring or anticoagula-
tion with UFH or LMWH for 6 weeks to 3 months. Should
thrombus progression occur, anticoagulation therapy is
suggested (2C). Meanwhile, ASH suggests anticoagulation
alone rather than no anticoagulation (2C) and rather than
thrombolysis (1C). In the case of RVT with thrombus
extension into the IVC, the same anticoagulation therapy
is suggested by CHEST (2C). In the case of bilateral RVT
with organ dysfunction, LMWH/UFH or initial thrombo-
lysis with tissue plasminogen activator and subsequent
LMWH/UFH therapy are suggested by CHEST (2C), in
line with ASH, which suggests thrombolysis followed by
anticoagulation in neonatal life-threatening RVT (2C).
Homozygous Protein C Deficiency
For neonates presenting with purpura fulminans due to
homozygous protein C deficiency, CHEST recommends the
administration of FFP 10–20 mL/kg 12-hourly or protein
C concentrate 20–60 units/kg until the lesions clear (1A).
ASH also suggests a protein C replacement therapy with or
without anticoagulation, rather than anticoagulation alone in
the neonatal period (2C). After which, lifelong treatment
with VKA or LMWH (1C), protein C replacement (1B), or
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liver transplantation (1C and ASH 2C) is recommended by
CHEST.
Structural Venous Anomalies
Secondary VTE due to structural venous anomalies should
be treated as first spontaneous VTEs (see above) according
to the CHEST guidelines. For recurrent VTEs, indefinite
anticoagulation is recommended until the venous anoma-
lies are removed or repaired surgically (2C).
Conclusion
Several recommendations for the treatment of VTE in chil-
dren have been published in the last decade. Although these
recommendations are of low evidence, and in part extrapo-
lated from adult guidelines, they provide an important type of
standard of care that helps pediatricians to decide the best
consensus treatment approach for VTE in their patients. The
CHEST, ASH, and UK guidelines show consistencies in their
recommendations and outline how to treat pediatric VTE in
a reasonably standardized manner.
Currently, multicenter randomized clinical trials with
new direct oral anticoagulants (DOACs) are ongoing.
These will not only provide new and potentially advanta-
geous therapeutic options for pediatric VTE, but also
deliver scientifically valuable data on the efficacy and
safety of new treatment options, and their risks and side
effects compared to standard anticoagulants for the treat-
ment and prevention of thrombotic events in children with
different clinical conditions.
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